HOME >> BIOLOGY >> NEWS
New collaborations offer hope for HIV/AIDS vaccine

WASHINGTON, DC - Prospects for a safe, effective AIDS vaccine are improving as researchers from the public and private sectors begin to collaborate in new and creative ways, researchers said today at the 2005 Annual Meeting of the American Association for the Advancement of Science (AAAS).

According to the Joint United Nations Programme on AIDS (UNAIDS) approximately 39 million people are living with HIV, and an estimated 4.9 million people were newly infected with HIV in 2004 alone.

New vaccines take decades to create, and the process can be slowed down when researchers work independently. Another reason that we don't have an AIDS vaccine yet is that making drugs for patients already infected with the virus has generally taken top priority.

"Given the magnitude of the AIDS epidemic and the complexity of the virus, the world must continue to galvanize resources to develop new prevention technologies, most importantly a vaccine," said Seth Berkley, president of the International AIDS Vaccine Initiative. "An effective AIDS vaccine is our best hope to stop the spread of HIV." Anthony S. Fauci M.D., director of the National Institute of Allergy and Infectious Diseases, said that for the National Institutes of Health, the new paradigm requires expanding beyond basic research. It involves a new focus on product development through alliances with the pharmaceutical industry and other research agencies.

"At NIH we are attempting to we strike a balance between the time-honored goals of pursuing basic scientific research as the true foundation of all our objectives, and the need for applied research, and novel research partnerships, to rapidly develop vaccines, therapies and other interventions," he said

Differences in study design and research methods can make it difficult to get the most out of vaccine trials as they are currently done, Fauci said. The leveling-off of NIH's research budget has added to the need for greater co
'"/>


21-Feb-2005


Page: 1 2

Related biology news :

1. New blood test might offer early warning of deep belly fat
2. UCF nanoparticle offers promise for treating glaucoma
3. Lucky 13 as new gene discovery offers further hope for childhood blindness
4. Largest synthetic gene ever built offers insights into anti-malarial drug resistance
5. Soils offer new hope as carbon sink
6. Gene therapy offers new hope for treatment of peripheral neuropathy
7. Sheep offer model for undernourishment in pregnant teen girls
8. Study of protein folds offers insight into metabolic evolution
9. Soy estrogens and breast cancer: Researcher offers overview
10. NIST building software offers green product advice
11. Scientists offer new view of photosynthesis

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New collaborations offer hope for HIV AIDS vaccine

(Date:5/23/2013)... carrying more than 284 million tons of cargo, transit the ... toll fees for the Panama Canal Authority. Each time a ... are used from Gatun Lake, which is also a source ... isthmus. , However, the advent of very large "super" ... at sea, has demanded change. The Panama Canal is being ...
(Date:5/23/2013)... Given the implications for the overall health, ... play a primary role in ensuring that all ... 60 minutes per day of vigorous or moderate-intensity ... Institute of Medicine. Recent estimates suggest that ... evidence-based guideline for promoting better health and development. ...
(Date:5/23/2013)... museums of the world are billions of animal and ... mushrooms and grasses, all stacked, stored and preserved in ... collections could be critical to understanding how the Earth,s ... human footprint if only the information were easily ... with the help of a team from the University ...
Breaking Biology News(10 mins):Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4
(Date:5/23/2013)... Graphite Metallizing Corporation announces a series ... stainless steel pillow blocks. This series combines the ... application and installation versatility of pillow blocks. , ... exceptionally well when submerged in water, water-soluble chemicals ... acids, alkalies, hydrocarbons, black liquor, and liquid gases. ...
(Date:5/23/2013)... The maker community is a contemporary ... They focus on learning practical skills while applying them ... bringing their ideas to life via crowdfunding. A subgroup ... making projects using biology. Glowing Plant has worked for ... them glow with bioluminescence genes, and has now pursued ...
(Date:5/23/2013)... Virobay, Inc. today announced that their development ... important milestone, as Virobay has now initiated a Phase ... S inhibitor.   The first Phase 1 ... designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics ... "The initiation of this Phase 1 trial with ...
(Date:5/23/2013)... Northwest Biotherapeutics (NASDAQ: NWBO ) ... personalized immune therapies for solid tumor cancers, announced today ... American Society Of Clinical Oncology (ASCO) meeting in ... in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ) ... pre-eminent conference focused on clinical treatment of cancer, with ...
Breaking Biology Technology:Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
Cached News: